Does the media favor APRE or QNCX?

In the previous week, Aprea Therapeutics had 10 more articles in the media than Quince Therapeutics. MarketBeat recorded 14 mentions for Aprea Therapeutics and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat Aprea Therapeutics' score of 0.08 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ESLA or APRE?

In the previous week, Aprea Therapeutics had 11 more articles in the media than Estrella Immunopharma. MarketBeat recorded 14 mentions for Aprea Therapeutics and 3 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.62 beat Aprea Therapeutics' score of 0.08 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GNTA or APRE?

Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 351.05%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger earnings and valuation, GNTA or APRE?

Genenta Science has higher earnings, but lower revenue than Aprea Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Aprea Therapeutics $290K 29.52 -$12.60M -$1.54 N/A

Do analysts recommend BCTX or APRE?

Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 351.05%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Aprea Therapeutics (APRE) Competitors

$0.68 +0.01 (+1.33%)

Closing price 03:50 PM Eastern

Extended Trading

$0.68 0.00 (-0.13%)

As of 07:37 PM Eastern

Compare

APRE vs. QNCX, ESLA, GNTA, SGMO, and BCTX

Should you buy Aprea Therapeutics stock or one of its competitors? Aprea Therapeutics's main competitors and comparable companies include Quince Therapeutics (QNCX), Estrella Immunopharma (ESLA), Genenta Science (GNTA), Sangamo Therapeutics (SGMO), and Briacell Therap (BCTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aprea Therapeutics compare to Quince Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Aprea Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Aprea Therapeutics has higher revenue and earnings than Quince Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	29.52	-$12.60M	-$1.54	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A

In the previous week, Aprea Therapeutics had 10 more articles in the media than Quince Therapeutics. MarketBeat recorded 14 mentions for Aprea Therapeutics and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat Aprea Therapeutics' score of 0.08 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aprea Therapeutics presently has a consensus target price of $3.07, indicating a potential upside of 351.05%. Quince Therapeutics has a consensus target price of $310.50, indicating a potential upside of 812.16%. Given Quince Therapeutics' higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

Quince Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Quince Therapeutics' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%
Quince Therapeutics	N/A	N/A	-67.99%

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Aprea Therapeutics beats Quince Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Estrella Immunopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Estrella Immunopharma presently has a consensus target price of $8.00, indicating a potential upside of 1,006.19%. Aprea Therapeutics has a consensus target price of $3.07, indicating a potential upside of 351.05%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Estrella Immunopharma has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Estrella Immunopharma's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-289.98%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aprea Therapeutics has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Aprea Therapeutics	$290K	29.52	-$12.60M	-$1.54	N/A

In the previous week, Aprea Therapeutics had 11 more articles in the media than Estrella Immunopharma. MarketBeat recorded 14 mentions for Aprea Therapeutics and 3 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.62 beat Aprea Therapeutics' score of 0.08 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aprea Therapeutics beats Estrella Immunopharma on 9 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Aprea Therapeutics had 13 more articles in the media than Genenta Science. MarketBeat recorded 14 mentions for Aprea Therapeutics and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.87 beat Aprea Therapeutics' score of 0.08 indicating that Genenta Science is being referred to more favorably in the media.

Company	Overall Sentiment
Genenta Science	Very Positive
Aprea Therapeutics	Neutral

Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 351.05%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Genenta Science has higher earnings, but lower revenue than Aprea Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Aprea Therapeutics	$290K	29.52	-$12.60M	-$1.54	N/A

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genenta Science has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Genenta Science's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Summary

Aprea Therapeutics beats Genenta Science on 7 of the 13 factors compared between the two stocks.

How does Aprea Therapeutics compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Aprea Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Aprea Therapeutics	$290K	29.52	-$12.60M	-$1.54	N/A

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sangamo Therapeutics has a net margin of -310.81% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Sangamo Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Aprea Therapeutics has a consensus price target of $3.07, suggesting a potential upside of 351.05%. Given Sangamo Therapeutics' higher probable upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

In the previous week, Aprea Therapeutics had 14 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 14 mentions for Aprea Therapeutics and 0 mentions for Sangamo Therapeutics. Aprea Therapeutics' average media sentiment score of 0.08 beat Sangamo Therapeutics' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Aprea Therapeutics	Neutral

Summary

Aprea Therapeutics beats Sangamo Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 351.05%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Briacell Therap has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Briacell Therap has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Aprea Therapeutics has higher revenue and earnings than Briacell Therap. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Aprea Therapeutics	$290K	29.52	-$12.60M	-$1.54	N/A

In the previous week, Aprea Therapeutics had 13 more articles in the media than Briacell Therap. MarketBeat recorded 14 mentions for Aprea Therapeutics and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 1.87 beat Aprea Therapeutics' score of 0.08 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Very Positive
Aprea Therapeutics	Neutral

Summary

Aprea Therapeutics beats Briacell Therap on 12 of the 14 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.45M	$3.71B	$6.98B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	N/A	10.68	269.86	25.30
Price / Sales	29.52	1,308.25	601.81	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	0.22	17.49	13.08	6.33
Net Income	-$12.60M	-$13.32M	$3.45B	$347.70M
7 Day Performance	4.55%	1.74%	1.12%	1.07%
1 Month Performance	-6.66%	1.60%	1.79%	1.03%
1 Year Performance	-59.77%	56.43%	67.69%	20.77%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	3.6609 of 5 stars	$0.68 +1.3%	$3.07 +351.0%	-60.8%	$8.45M	$290K	N/A	7	News Coverage Earnings Report Analyst Forecast Analyst Revision Gap Up
QNCX Quince Therapeutics	2.9895 of 5 stars	$32.73 +6.8%	$310.50 +848.7%	-90.6%	$31.17M	N/A	N/A	60	News Coverage Earnings Report Analyst Upgrade
ESLA Estrella Immunopharma	2.6601 of 5 stars	$0.71 -2.3%	$8.00 +1,034.6%	-14.7%	$31.07M	N/A	N/A	N/A	Earnings Report Analyst Downgrade
GNTA Genenta Science	0.5244 of 5 stars	$1.30 flat	N/A	-59.4%	$30.67M	N/A	N/A	7	Positive News
SGMO Sangamo Therapeutics	0.9503 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. QNCX, ESLA, GNTA, SGMO, and BCTX

How does Aprea Therapeutics compare to Quince Therapeutics?

Summary

How does Aprea Therapeutics compare to Estrella Immunopharma?

Summary

How does Aprea Therapeutics compare to Genenta Science?

Summary

How does Aprea Therapeutics compare to Sangamo Therapeutics?

Summary

How does Aprea Therapeutics compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. QNCX, ESLA, GNTA, SGMO, and BCTX

How does Aprea Therapeutics compare to Quince Therapeutics?

Which has more risk & volatility, APRE or QNCX?

Which has preferable earnings and valuation, APRE or QNCX?

Does the media favor APRE or QNCX?

Do analysts recommend APRE or QNCX?

Is APRE or QNCX more profitable?

Do insiders & institutionals believe in APRE or QNCX?

Summary

How does Aprea Therapeutics compare to Estrella Immunopharma?

Which has more volatility & risk, ESLA or APRE?

Do analysts prefer ESLA or APRE?

Is ESLA or APRE more profitable?

Do insiders and institutionals hold more shares of ESLA or APRE?

Which has higher earnings and valuation, ESLA or APRE?

Does the media refer more to ESLA or APRE?

Summary

How does Aprea Therapeutics compare to Genenta Science?

Does the media refer more to GNTA or APRE?

Do analysts rate GNTA or APRE?

Which has stronger earnings and valuation, GNTA or APRE?

Do institutionals and insiders hold more shares of GNTA or APRE?

Is GNTA or APRE more profitable?

Which has more risk and volatility, GNTA or APRE?

Summary

How does Aprea Therapeutics compare to Sangamo Therapeutics?

Which has better valuation and earnings, SGMO or APRE?

Do institutionals & insiders hold more shares of SGMO or APRE?

Is SGMO or APRE more profitable?

Do analysts recommend SGMO or APRE?

Which has more risk & volatility, SGMO or APRE?

Does the media refer more to SGMO or APRE?

Summary

How does Aprea Therapeutics compare to Briacell Therap?

Do analysts recommend BCTX or APRE?

Is BCTX or APRE more profitable?

Do insiders & institutionals hold more shares of BCTX or APRE?

Which has more volatility & risk, BCTX or APRE?

Which has higher earnings & valuation, BCTX or APRE?

Does the media prefer BCTX or APRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools